Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rapid Nexus is a medical technology company dedicated to developing advanced solutions for chronic and non-healing wounds. The company's core technology integrates Cold Atmospheric Plasma (CAP) with nanotechnology to address the complex challenges of wound care, such as bacterial biofilms and impaired tissue regeneration. Their flagship products are designed to provide non-invasive, effective treatments for diabetic foot ulcers and other hard-to-heal wounds. By focusing on point-of-care applications, Rapid Nexus aims to significantly reduce the risk of amputations and improve the quality of life for patients with chronic conditions. The company operates at the intersection of biotechnology and medical devices to deliver next-generation wound healing therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rapid Nexus Nanotech Wound Solutions.